Cue Biopharma (NASDAQ:CUE) is a biopharmaceutical company pioneering the development of a novel class of injectable biologics to selectively engage and modulate target T cells directly within the patient's body. The company's proprietary platform, the Immuno-STAT™ (Selective Targeting and Alteration of T cells) technology, is designed to harness the body's intrinsic immune system without the need for ex vivo manipulation. Cue Biopharma's strategy focuses on creating safer, more effective therapies that can address a wide range of diseases, including cancer, autoimmune disorders, and infectious diseases. Their active projects span multiple stages of preclinical and clinical development, aiming to validate the Immuno-STAT platform's versatility and its potential to revolutionize current treatment paradigms by providing targeted, durable, and controllable immune modulation.